目的 探讨地西他滨(DAC)联合沙利度胺对骨髓增生异常综合征(MDS)患者的病态造血及疗效的影响。方法 以本院自2014年6月—2020年5月收治的MDS患者为研究总体,行便利抽样法选择60例于收治期间行输血、抗感染及诸如促红生成素 (EPO)+集落刺激因子(CSF)等细胞因子治疗效果不佳的MDS开展研究,按完全区化原则设立对照组及观察组,予以对照组沙利度胺治疗,观察组则于对照组基础上施予地西他滨(DAC)行联合治疗,比较2组疗效、血象相关指标、病态造血改善情况及预后转归。结果 观察组ORR为51.61%,与对照组的26.67%相比更高,差异有统计学意义(P<0.05);经治疗,2组血小板计数(PLT)、血红蛋白(HGB)、中性粒细胞计数(ANC)水平均见一定程度上升,骨髓原始细胞(bls)水平则见下降,观察组PLT、HGB、ANC相较于对照组更高,bls水平则更低(P<0.05);于2020年5月截止随访,随访时间8~96个月,中位随访时间68个月。于治疗及随访中行骨髓形态检查及染色体核型鉴别均表现正常。关于病态造血改善情况,2组T1率比较,差异无统计学意义(P>0.05);观察组国际预后积分系统评分整体优于对照组(P<0.05);2组Ⅰ~Ⅳ级不良反应比较,差异无统计学意义(P>0.05);观察组5年总生存时间率为63.33%,相较于对照组的36.67%更高(P<0.05)。结论 相较于单一沙利度胺治疗,应用地西他滨联合沙利度胺治疗MDS,疗效更为确切,且可改善血象指标,拥有一定T1率,且预后转归表现较好。

Objective To investigate the impact of decitabine (DAC) combined with thalidomide on dyshaematopoiesis and efficacy in patients with myelodysplastic syndrome (MDS). Methods Patients with MDS admitted to our hospital from June 2014 to May 2020 were selected as the research population.Among them, 60 MDS cases were selected by convenience sampling method, which had poor therapeutic effect with treatment of blood transfusion, anti-infection and cytokines treatments such as erythropoietin (EPO)+ colony stimulating factor (CSF). The control group and the observation group were set up according to the principle of complete block, and the control group was treated with thalidomide while the observation group was treated with decitabine (DAC) on the basis of the control group.The efficacy, hemogram-related indicators, improvement of dyshaematopoiesis and prognosis outcomes were compared between the two groups. Results The overall response rate (ORR) of the observation group was higher than that of the control group (51.61%vs 26.67%, P<0.05). After treatment, the levels of platelet (PLT), hemoglobin (HGB) and absolute neutrophil count (ANC) in the two groups were increased to a certain extent while the level of bone marrow blasts(bls) was decreased, and the levels of PLT, HGB and ANC of the observation group were higher than those of the control group while the level of bls was lower (P<0.05). The follow-up deadline was May 2020, and the follow-up time was 8-96 months and the median follow-up time was 68 months.During treatment and follow-up, bone marrow morphology examination and chromosome karyotype identification results were normal.Regarding the improvement of dyshaematopoiesis, the difference in T1 rate between the two groups was not statistically significant (P>0.05). The revised International Prognostic Scoring System prognosis score of the observation group was better than that of the control group (P<0.05). There were no statistically significant differences between the two groups in terms of grade I~IV adverse reactions (P>0.05). The 5-year overall survival rate of the observation group was 63.33%, which was higher than 36.67%of the control group (P<0.05). Conclusion Compared with thalidomide only treatment, the application of decitabine combined with thalidomide in the treatment of MDS had a more accurate efficacy, improved hemogram indicators, and had a certain T1 rate and good prognosis outcomes.

目的 观察地西他滨与小剂量CAG方案治疗白血病的短期疗效。方法 选取66例AML患者进行前瞻性研究,按随机数表法分为观察组与对照组,各33例。观察组采取地西他滨与小剂量CAG方案进行治疗,对照组采取标准CAG方案,两组接受相同的支持治疗,均治疗1个疗程。比较两组化疗结束后4周的完全缓解率(CRR)、总缓解率(ORR)、红细胞输注量、血小板输注量、抗生素应用情况、不良反应发生率。结果 观察组CRR与CRR分别为69.70%与81.82%,高于对照组39.40%与57.58%（P<0.05）。两组红细胞输注量、血小板输注量、抗生素应用次数的差异均无统计学意义（P>0.05）。两者均未见肾功能损伤与治疗相关死亡患者。两组肝功能异常与恶心呕吐总发生率的差异及血小板减少与粒细胞缺乏的严重程度均无统计学意义（P>0.05）。结论 地西他滨联合小剂量CAG方案治疗白血病可提高疗效,且不增加不良反应,是治疗AML的有效方案之一。